Index - P/E - EPS (ttm) - Insider Own 74.74% Shs Outstand 19.51M Perf Week 0.50%
Market Cap 214.12M Forward P/E - EPS next Y - Insider Trans 80.03% Shs Float 4.93M Perf Month -
Income - PEG - EPS next Q - Inst Own - Short Float - Perf Quarter -
Sales - P/S - EPS this Y - Inst Trans - Short Ratio - Perf Half Y -
Book/sh - P/B - EPS next Y - ROA - Short Interest - Perf Year -
Cash/sh - P/C - EPS next 5Y - ROE - 52W Range 9.40 - 12.30 Perf YTD 2.38%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -10.77% Beta -
Dividend TTM - Quick Ratio - Sales past 5Y 0.00% Gross Margin - 52W Low 16.82% ATR (14) 1.38
Dividend Ex-Date - Current Ratio - EPS Y/Y TTM - Oper. Margin - RSI (14) - Volatility 12.11% -
Employees 58 Debt/Eq - Sales Y/Y TTM - Profit Margin - Recom - Target Price -
Option/Short No / Yes LT Debt/Eq - EPS Q/Q - Payout - Rel Volume 0.11 Prev Close 10.90
Sales Surprise - EPS Surprise - Sales Q/Q - Earnings - Avg Volume 223.03K Price 10.98
SMA20 2.07% SMA50 2.07% SMA200 2.07% Trades
Volume 3,571 Change 0.69%
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Northpond Ventures II GP, LLC 10% Owner Oct 15 '24 Buy 11.00 763,636 8,399,996 763,636 Oct 17 06:34 PM AH Equity Partners Bio I, L.L. 10% Owner Oct 15 '24 Buy 11.00 727,272 7,999,992 1,579,885 Oct 17 05:05 PM Enavate Sciences GP, LLC 10% Owner Oct 15 '24 Buy 11.00 1,363,636 14,999,996 3,785,802 Oct 17 04:15 PM Polaris Management Co. VII, L. 10% Owner Oct 15 '24 Buy 11.00 909,090 9,999,990 909,090 Oct 15 06:00 PM 5AM Partners VI, LLC 10% Owner Oct 15 '24 Buy 11.00 909,090 9,999,990 2,625,145 Oct 15 05:56 PM Nashat Amir Director Oct 15 '24 Buy 11.00 909,090 9,999,990 909,090 Oct 15 05:49 PM Schwab Andrew J. Director Oct 15 '24 Buy 11.00 909,090 9,999,990 2,625,145 Oct 15 05:48 PM Cohenour Jason Director Jun 05 '24 Sale 0.83 8,640 7,176 0 Jun 06 09:00 AM Cohenour Jason Director Mar 05 '24 Option Exercise 0.00 7,824 0 10,962 Mar 07 07:41 PM Scott Richard M. Chief Legal Officer, Secretary Nov 05 '23 Option Exercise 0.00 3,167 0 53,090 Nov 07 02:48 PM
Index RUT P/E - EPS (ttm) -3.91 Insider Own 39.77% Shs Outstand 30.34M Perf Week 15.07%
Market Cap 149.42M Forward P/E - EPS next Y -1.17 Insider Trans -4.23% Shs Float 18.27M Perf Month 22.82%
Income -42.29M PEG - EPS next Q -0.25 Inst Own 43.37% Short Float 6.65% Perf Quarter -16.53%
Sales 0.00M P/S - EPS this Y 81.51% Inst Trans 145.38% Short Ratio 3.76 Perf Half Y -61.67%
Book/sh 2.59 P/B 1.90 EPS next Y -17.96% ROA -94.50% Short Interest 1.21M Perf Year 89.42%
Cash/sh 2.74 P/C 1.80 EPS next 5Y - ROE -130.08% 52W Range 1.44 - 19.41 Perf YTD 81.07%
Dividend Est. - P/FCF - EPS past 5Y 32.94% ROI -57.98% 52W High -74.63% Beta 1.80
Dividend TTM - Quick Ratio 6.07 Sales past 5Y 0.00% Gross Margin - 52W Low 242.01% ATR (14) 0.53
Dividend Ex-Date - Current Ratio 6.07 EPS Y/Y TTM 49.18% Oper. Margin 0.00% RSI (14) 57.98 Volatility 13.20% 13.04%
Employees 11 Debt/Eq 0.07 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 18.00
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q 74.45% Payout - Rel Volume 0.18 Prev Close 4.94
Sales Surprise - EPS Surprise -2.56% Sales Q/Q - Earnings Aug 09 AMC Avg Volume 323.28K Price 4.93
SMA20 20.87% SMA50 0.07% SMA200 -39.74% Trades
Volume 8,495 Change -0.30%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-30-24 Initiated Scotiabank
Sector Outperform
$20
Sep-10-24 Initiated JMP Securities
Mkt Outperform
$15
Jul-09-24 Initiated Craig Hallum
Buy
$18
May-23-24 Initiated Cantor Fitzgerald
Overweight
$21
Apr-12-24 Initiated Oppenheimer
Outperform
$25
Oct-21-24 07:00AM
Sep-23-24 07:00AM
Sep-03-24 07:00AM
Aug-26-24 07:00AM
Aug-23-24 06:45PM
07:00AM
Loading…
Aug-22-24 07:00AM
Aug-09-24 05:59PM
Jul-24-24 07:30AM
06:00AM
Jul-11-24 07:15AM
07:00AM
Jul-03-24 07:00AM
Jul-01-24 11:13AM
07:00AM
Jun-25-24 07:00AM
08:22AM
Loading…
Jun-10-24 08:22AM
(FierceBiotech.com) -8.78%
07:00AM
Jun-03-24 07:00AM
May-17-24 04:12PM
May-10-24 07:00AM
May-07-24 11:59AM
Apr-30-24 07:00AM
Apr-23-24 07:00AM
Apr-10-24 08:00AM
Mar-11-24 09:20AM
Mar-04-24 07:00AM
Feb-26-24 07:00AM
Feb-07-24 07:00AM
Jan-29-24 08:00AM
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Schwab Andrew J. Director Sep 11 '24 Sale 6.60 252,500 1,666,500 66,356 Sep 13 06:56 PM Schwab Andrew J. Director Sep 13 '24 Sale 6.06 13,837 83,852 66,277 Sep 13 06:56 PM 5AM Partners VII, LLC 10% Owner Sep 11 '24 Sale 6.60 252,500 1,666,500 66,356 Sep 13 06:54 PM 5AM Partners VII, LLC 10% Owner Sep 13 '24 Sale 6.06 13,837 83,852 66,277 Sep 13 06:54 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
